Skip to content
Screener

Amgen AMGN Product sales — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.7B+23.0%
Prolia
$759M-32.4%
EVENITY
$714M+37.8%
ENBREL
$580M-4.0%
TEPEZZA
$576M+14.1%
Otezla
$491M-20.6%
TEZSPIRE
$486M+42.1%
BLINCYTO
$472M+22.9%
Nplate
$430M+16.5%
KRYSTEXXA
$400M+14.6%
Aranesp
$352M-1.9%
XGEVA
$352M-33.8%
Vectibix
$338M+10.8%
UPLIZNA
$335M+90.3%
KYPROLIS
$314M-16.9%
IMDELLTRA/IMDYLLTRA
$288M+115%

Similar metrics at other companies

Kratos Defense & Security Solutions logo
KTOSProduct sales — Total revenues
$237M+18.4%
MML
MMLPProduct Sales — Total revenues
$128.97M+28.5%
Bausch + Lomb logo
BLCOProduct sales — Total revenues
$1.39B+9.2%
Gilead Sciences logo
GILDProduct sales — Total revenues
$7.63B+8.1%
Quanterix Corporation logo
QTRXProduct revenue — Total revenues
$25.48M+22.9%
Cactus logo
WHDProduct revenue — Total revenues
$297.24M+42.2%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$220.64B+44.0%
Enterprise value$277.37B+32.8%
P/E25.2×+2.1×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Revenues:
Product sales$9,537$8,771$17,755$16,644
Other revenues517408917684
Total revenues10,0549,17918,67217,328
Operating expenses:
Cost of sales2,8113,0115,5555,979
Research and development1,8681,7443,5873,230
Selling, general and administrative1,7451,6913,3473,378

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's product sales — total revenues?
Amgen (AMGN) reported product sales — total revenues of $9.54B in Q2 2026.
How has Amgen's product sales — total revenues changed year-over-year?
Amgen's product sales — total revenues increased by 8.7% year-over-year, from $8.77B to $9.54B.
What is the long-term trend for Amgen's product sales — total revenues?
Over 4 years (2021 to 2025), Amgen's product sales — total revenues has grown at a 9.7% compound annual growth rate (CAGR), from $24.3B to $35.15B.
What does product sales — total revenues mean?
This metric represents the total gross revenue generated from the sale of therapeutic products within a specific business segment. It reflects the market demand and commercial success of the company's portfolio of drugs and biotechnology treatments. Monitoring this figure helps assess the top-line growth trajectory and the effectiveness of the commercialization strategy for the segment's product offerings.

Ask your AI about Amgen's product sales — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude